About the Company
we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $KRTX News
PureTech made millions on Karuna acquisition. Here’s what it plans to return to shareholders.
Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a ...
PureTech's newest biotech spinout represents a shift from the past
Building on Karuna’s success after its recent acquisition by Bristol Myers Squibb, PureTech aims to create what they’re ...
Loss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-Term
Snowflake stock has dived in recent weeks, but Guggenheim says the cloud computing company can bounce back from its recent ...
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics
Bristol Myers Squibb (BMS) has successfully completed its acquisition of Karuna Therapeutics, Inc. Through this transaction, ...
Bristol Myers Squibb closes $14B Karuna deal
Bristol Myers Squibb said it completed its previously announced acquisition of Karuna Therapeutics Inc. – a Boston-based ...
Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short Position
Amalthea Fund featured stocks like Karuna Therapeutics, Inc. (NASDAQ:KRTX) in the fourth quarter 2023 investor letter.
Karuna Therapeutics Inc KRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Bristol Myers Squibb Completes Acquisition Of Karuna Therapeutics - Quick Facts
Bristol Myers Squibb (BMY) has successfully completed its acquisition of Karuna Therapeutics, Inc. Karuna shares have ceased trading ...
Karuna Therapeutics Inc (KRTX)
Anavex Life Sciences (NASDAQ:AVXL) Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the ...
KRTX Karuna Therapeutics, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Karuna Therapeutics Inc (KRTX)
Investing in mid-cap stocks is essential for investors who prefer a diversified portfolio. These stocks offer a middle ground with regard to the risks and rewards when compared to ...
Loading the latest forecasts...